Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114414 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL29435883 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL21810899 | 0.95 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL19814625 | 0.95 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL1921572 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL15353020 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| Ammonia Solution, Strong SCHEMBL7412270 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL10442032 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL27615166 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 | |
| Ammonia Solution, Strong SCHEMBL16042040 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | SMN1; SMN2 4611/4885L3MBTL1 2244/4885NOS3 1323/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | SMN1; SMN2 4601/4885L3MBTL1 2510/4885NOS3 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.